NEW YORK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Endo International PLC (“Endo” or the “Company”) (NASDAQ: ENDP ) of the January 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Endo stock or options between February 25, 2014 and November 3, 2016 (the “Class Period”). The case, Shasha v. Endo International PLC et al , No. 16-cv-08645 was filed on November 7, 2016.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that one of its subsidiaries had engaged in potential pricing collusion activities that would prompt a Department of Justice (“DOJ”) antitrust investigation that could lead to potential criminal charges against the Company.
On September 28, 2015, Endo announced that it had completed its $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. (“Par Pharmaceutical”) from the private investment firm TPG. Then, on November 3, 2016, Bloomberg published the article titled “U.S. Charges in Generic-Drug Probe to Be Filed by Year End” which discussed the DOJ’s two year investigation of suspected price collusion by several pharmaceutical companies, including Par Pharmaceutical.
After the announcement, KLX’s share price fell from $18.17 per share on November 2, 2016 to a closing price of $14.63 on November 3, 2016—a $3.54 or a 19.5% drop.
Request more information now by clicking here: www.faruqilaw.com/ENDP . There is no cost or obligation to you.
Take Action
If you invested in Endo stock or options between February 25, 2014 and November 3, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/ENDP . You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com . Faruqi & Faruqi, LLP also encourages anyone with information regarding Endo’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. rgonnello@faruqilaw.com Telephone: (877) 247-4292 or (212) 983-9330
